ArticleActa Cardiologica Sinica2021
Complement C1q/Tumor Necrosis Factor-Related Protein-3 (CTRP3) is Significantly Decreased in Patients with Heart Failure and Closely Related with Ventricular Tachycardia.
Article in Acta Cardiologica Sinica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 8 citations in OpenAlex.
- Serum CTRP3 and CysC correlate with glucose, lipid, and bone metabolism in elderly patients with type 2 diabetes mellitus complicated with osteoporosis.Journal of diabetes investigation · 2026Article
- Multifunctional Roles and Therapeutic Prospects of C1q/TNF-Related Protein 3 (CTRP3) in Human Diseases.Current medical science · 2025Review
- The Role of Anti-Inflammatory Adipokines in Cardiometabolic Disorders: Moving beyond Adiponectin.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe relationship between serum complement C1q/tumor necrosis factor (TNF)-related protein-3 (CTRP3) levels and ventricular tachycardia (VT) in heart failure patients with reduced ejection-fraction (HFrEF) is unclear. The aim of this study was to investigate changes in serum CTRP3 level and the relationship with VT in HFrEF.
methodsThe study included 88 patients with HFrEF with and without VT and 30 age- and sex-matched healthy controls. Serum CTRP3 levels were measured in addition to routine anamnesis, physical, laboratory and echocardiography examinations. The patients were divided into groups with and without HFrEF and HFrEF patients with and without VT.
resultsSerum CTRP3 levels were significantly lower in the patients with HFrEF than in the control group (206 ± 16 ng/mL and 427 ± 49 ng/mL, p < 0.001). Similarly, CTRP3 levels were lower in the patients with VT (194 ± 10 ng/mL and 216 ± 15 ng/mL, p < 0.001). Left ventricular (LV) volume and tricuspid regurgitation pressure gradient were significantly higher and LV ejection-fraction was significantly lower in the patients with VT (all p < 0.05). Serum CTRP3 and LV end-systolic volume values independently determined the patients with VT (all p < 0.01). Every 10 ng/mL decrease in CTRP3 level increased the odds ratio of VT by 79%. In the receiver operating characteristic curve (ROC) analysis, the area under the ROC curve for CTRP3 was 0.884 (p < 0.001). A CTRP3 cut-off value of 200 ng/mL could predict VT with 88.1% sensitivity and 80.2% specificity.
conclusionsSerum CTRP3 levels were significantly decreased in the patients with HFrEF, and decreased CTRP3 levels were very closely related to the presence of VT in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.